|Videos|October 13, 2021
Novel Agents Emerging in the Lung Cancer Pipeline
Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.
Advertisement
Episodes in this series
Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.
Advertisement
Related to this article
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.
Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.
In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5